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including discrimination between the thrombotic and atherosclerotic plaque com-
ponents. We sought to investigate the feasibility of thrombus quantification and its
monitoring in patients with high thrombotic burden acute coronary syndromes.
Methods: Patients with successfully revascularized acute coronary syn-
dromes and a large thrombus burden on initial coronary angiography who ben-
eficiated from repeated TD-OCT examinations in our institution were suitable
for inclusion. Coronary lesion stenosis degree was determined by quantitative
coronary angiography (QCA) methods. Thrombus volume, maximal surface and
minimal luminal area (MLA) were quantified by serial area measurement within
the athero-thrombotic culprit lesion in 1 mm intervals before any stenting.
Results: Eleven patients underwent 2 consecutive TD-OCT examinations.
The OCT image quality was suitable for thrombus quantification in n=9 subjects
(89% men/ age=62.4±5.7y/ 89% STEMI). All patients were under anticoagulant
and dual antiplatelet therapy between the two procedures (mean delay: 4.1±
0.4 days). No adverse events were observed following OCT analysis.
We measured a progressive reduction of thrombus burden between the two
analysis, as assessed by the decrease of thrombus volume (5.3±1.7
vs.11.0±3.4 mm3, p=0.004), length (7.4±1.0 vs. 10.9±1.8 mm, p=0.02) and
increase of MLA (2.5±0.6 mm2 vs. 1.8±0.3 mm2, p=0.02). However, the
degree of stenosis analyzed by QCA didn’t significantly decrease over time
(49.7±4.6% vs. 55.7±6.6%, p= 0.15). The thrombus volume reduction was
time dependent, as witnessed by the high correlation between the percentage
of thrombus volume decrease and the delay between analysis (R=0.87,
p=0.002). The observed thrombus volume reduction rate was evaluated to
12% of the initial volume per day under medical therapy.
Conclusion: TD-OCT assessment of thrombus volume in patients with
ACS is feasible, safe and could allow in vivo clot regression monitoring.
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Background: We report on the management of and processes of care in
consecutive patients with Takotsubo syndrome using data from a French reg-
istry (OFSETT).
Methods: Between November 2010 and December 2011, 15 non-academic
hospitals included consecutive patients diagnosed with Takotsubo syndrome
according to the Mayo clinic diagnostic criteria.
Results: A total of 121 patients were enrolled: 89% were women and the
mean age was 72±12 years. Most of the women (89%) were >50 years’ old; 8%
of patients had diabetes, 30% were current smokers and 52% had hypertension.
Symptoms of Takotsubo syndrome were chest pain (81%), dyspnoea (27%) and/
or syncope (5%). The mean maximum troponin level was 7.8 ng/mL and the
mean maximum B-type natriuretic peptide level was 1013 pg/mL. ECG showed
a negative T wave in 73%, ST elevation in 42% and/or a new Q wave in 29%
of patients. One patient was treated with fibrinolysis. Coronary angiography was
performed in all patients. Coronary arteries were angiographically normal in
78% of patients and showed <50% stenosis in 22%. Left ventricle (LV) angio-
graphy showed apical ballooning in 35% of patients. The mean LV ejection
fraction was 42±13% on echocardiography and 46±10% on angiography. The
target event was identified in 55% of the patients: mental stress in 61% and
physical stress in 29%. In-hospital treatment included nitrates (11% of patients),
unfractionated heparin (25%), low-molecular-weight heparin (79%), aspirin
(91%), antiplatelets (82%), and angiotensin-converting enzyme inhibitors/angio-
tensin receptor inhibitors (ACE/ARB) (75%). None of the patients died during
hospitalization. At discharge, patients were treated with aspirin (59%), statins
(46%), beta-blockers (75%), ACE/ARB (79%) and/or neurotropic agents (26%).
Conclusion: These observational data from 15 non-academic French hos-
pitals provide insights into the characteristics of patients with Takotsubo syn-
drome and current processes of care for this population.
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Objective: To investigate whether elevated triglycerides and low high-den-
sity lipoprotein (HDL) cholesterol (atherogenic dyslipidemia) are predictive of
risk for silent myocardial ischemia (SMI) or angiographic coronary artery dis-
ease (CAD) in asymptomatic patients with type 2 diabetes.
Methods: Cohort study in 1080 asymptomatic patients with type 2 dia-
betes, a normal 12-lead resting electrocardiogram (ECG), at least one addi-
tional cardiovascular risk factor and low density lipoprotein (LDL) cholesterol
<3.4 mmol/L. Patients initially underwent screening for SMI by 201thallium
myocardial scintigraphy after an ECG stress test, a pharmacological stress test
(dipyridamole injection), or both. Patients with SMI underwent coronary angi-
ography.
Results: SMI was detected in 292 patients and CAD in 91 patients.
Overall, 60 (5.5%) patients had atherogenic dyslipidemia (triglycerides
≥2.04 g/l mmol/L and HDL cholesterol ≤0,34 g/l), which was associated with
SMI (40.0 vs 26.3%, p<0.001) and CAD (22.2 vs 8.3%, p<0.001). In multi-
variate analyses taking into account the parameters associated in univariate
analyses with SMI and then CAD, SMI was associated with atherogenic dys-
lipidemia (odds ratio 1.8[1.0-3.3]), male gender (OR 2.1[1.5-2.9]), BMI (OR
0.97[0.94-1.00]), retinopathy (OR 1.4[1.1-1.9]), peripheral occlusive arterial
disease (POAD: OR 2.5[1.6-3.8]) and mean blood pressure (OR 1.01[1.00-
1.03]); CAD was associated with atherogenic dyslipidemia (OR 4.0[1.7-9.2]),
male gender (OR 3.0[1.6-5.6]), BMI (OR 0.94[0.90-1.00]), retinopathy
(OR 1.7[1.0-2.9], POAD (OR 4.0[2.1-7.4]) and mean blood pressure
(OR 1.03[1.01-1.05]). In the subgroup of 584 patients at LDL cholesterol
<2.6 mmol/L, CAD was also independently associated with atherogenic dys-
lipidemia (2.96 [0.97-9.03], p=0.06).
Conclusions: In type 2 diabetic patients including those at LDL cholesterol
goal, atherogenic dyslipidemia is associated with an increased risk of silent
CAD. Management targeted to this dyslipidemic profile may help to reduce
the high residual burden of cardiovascular disease.
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There are evidences of a link between platelet reactivity inhibition and
thrombotic and bleeding events. We have previously demonstrated that PR
after prasugrel loading dose (LD) predicts short-term thrombotic events. We
aimed to further investigate the relationship between PR under prasugrel and
one-year thrombotic and bleeding events.
Method: Patients were prospectively included in this multicentre study if
they had a successful PCI for an acute coronary syndrome (ACS) and received
prasugrel. Vasodilator-Stimulated Phosphoprotein (VASP index) was mea-
sured after prasugrel LD. Endpoint included the rate of thrombotic events (car-
diovascular death, myocardial infarction and stent thrombosis) and bleeding
events (TIMI) at one year.
© Elsevier Masson SAS. All rights reserved.
 
14 Archives of Cardiovascular Diseases Supplements (2013) 5, 1-18
Results: Three hundreds and one patients were enrolled. Nine patients (3%)
were lost to follow-up at one year. The rates of thrombotic and bleeding events
at one year were 7.5 and 6.8% respectively. The mean VASP index after a
60 mg LD of prasugrel was 34}23% and 76 patients (25%) were considered as
having high on-treatment platelet reactivity (HTPR). Patients with HTPR had a
higher rate of thrombotic events compared to good responders (19.7 vs
3.1%;p<0.001). Patients with a minor or major non-CABG related TIMI
bleeding had lower PR compared to patients with no bleeding events (21}18 vs
35}23%;p=0.008). In multivariate analysis, the VASP index predicted both
thrombotic and bleeding events (OR: 1.44 (95% CI: 1.2-1.72; p<0.001 and 0.75
(95% CI: 0.59-0.96;p=0.024 (respectively, per 10% increase)).
Conclusion: Platelet reactivity measurement after prasugrel LD predicts
both ischemic and bleedings events at one year follow-up for ACS patients
undergoing PCI.
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Background: Myocardial bridge (MB) is congenital myocardial band
overriding a portion of a coronary artery, mainly LAD. Incidence on coronary
angiography (CA) appears lesser than on autopsy, which can be ethnics-
related, while clinically all forms of coronary artery disease (CAD) are
reported: from benign arrhytmias up to sudden death.
Aim: We sought to determine incidence of MBs in the Serbian population
along with respective clinical features.
Methods: Retrospective analysis was carried out in the same population,
during the same 1-year time-frame and comprised consecutive: (A) 721 autop-
sies, with LM studies of the tunneled vessel (TV) wall together with the mor-
phometric analysis of the ventricular myocardium supplied by TV
(experimental group) and the ventricular myocardium of the same heart but
with a different blood supply (control group); (B) 4510 CA of symptomatic
patients were re-assessed for presence of MBs.
Results: (A) MBs were described in 6 cases (0.8%): 5 male, all over 70yrs.
Only single MB over LAD were found, while all showed: a) TV' intensive
atherosclerotic changes proximal to MB, only focal in the tunneled part;
b) intensive interstitial fibroses of the TV-supplied myocardium. (B) MBs
were found in 42pts (0.93%): 33 male, aged of 55+11yrs, with single MB over
the mid-LAD. 29% were CAD-free, 43% had 1-vessel CAD, 2-v-CAD (24%)
and 3-v-CAD (4%). MBs were most frequent in hearts with right coronary
dominance (69%). Hypertension and smoking were equally present (69%),
dyslipidemia (59%), family history of CAD (48%) and diabetes (21%). Pts
presented with stable angina (40%), nonspecific symptoms (14%), unstable
angina (7%) and supraventricular arrhythmia (5%), with a history of an ante-
rior wall STEMI vs. NSTEMI in 26% vs. 7%.
Conclusions: This first overview of MBs-incidence in Serbia (0.8% on
autopsy vs. 0.9% on CA) might underestimate its actual presence, which
prompted us to continue prospectively.
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Background: Microalbuminuria and uric acid are emerging as new coronary
risk factors in diabetics and non diabetics, their prevalence as well as their prog-
nostic value in patients with acute coronary syndrome (ACS) are still unclear.
Methods: We propose a prospective study of 175 patients admitted with
ACS with ST segment elevation (mean age of 57, 7±9.6 years (28-89 years),
71% are male, 53% are diabetics, 44% are hypertensive, 12% are followed for
chronic renal failure and 14.7% are overweight. The SCA affected the anterior
territory in 51% of cases. A primary angioplasty was performed in 26% of
cases and a fibrinolysis in 52% of cases.
Results: Microalbuminuria is positive in 22% of cases, affecting 42% of
diabetics and 8.7% of non diabetics, the rate of microalbuminuria is correlated
with the blood sugar level in diabetic and non diabetic (r=0.650, p=0.01 and
r=0.687, p=0.02). 
The uric acid is correlated to the serum creatinine level and the peak of tro-
ponin in patients with a creatinine clearance> 60 ml/mn (r=0.690, P=0.02 and
r=0.740, p=0.001). The uric acid is also correlated to the number of affected
coronary arteries (r=0.602, p=0.02). The rate of microalbuminuria is correlated
to the distribution of atherosclerosis 13±8 mg in single vessel disease vs.
15±7 mg in two vessel disease Vs 29±5 mg in three vessel disease, p=0.02. In
univariate and multivariate analysis, 56% of patients who have microalbumin-
uria presented a three vessel disease vs 23% among other patients, p=0.01,
OR=6.9 (95% ICA 1.7-23) independently of diabetes and hypertension.
Conclusion: The uric acid is not correlated to the diffusion of atheroscle-
rosis after adjustment to diabetes and kidney failure.
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Aim: Even if the recommended duration for dual antiplatelet therapy
(DAT) after non ST elevation acute coronary syndromes (NSTE-ACS) is
12 months, evidence concerning the benefit of clopidogrel adjunction espe-
cially beyond 3 months remains poor. The aim of the study was to assess the
effective clopidogrel intake and the incidence of a composite endpoint
including all causes death and non fatal myocardial infarction in a Tunisian
population after NSTE-ACS.
Methods: We included patients admitted for NSTE-ACS in our depart-
ment between January 2010 and August 2011 for whom long term evalu-
ation was possible. In-hospital deaths were excluded (including post
operative deaths). By telephone follow up, we evaluated the effective DAT
duration and the occurrence of all causes death and non-fatal myocardial
infarction.
Results: One hundred thirty patients were included. Mean (SD) follow up
was 261 (99) days. DAT was effectively observed during 94±103 days
(extremes ranging from 0 to 360 days). Angioplasty was performed in 51.5%,
coronary artery bypass graft in 8.4% and medical therapy was considered in
40.1%. In 35 (26.9%) patients, aspirin was the only antiplatelet therapy taken
after discharge although DAT was prescribed; 46.9% of the patients took the
DAT for more than 3 months, and 23.1% for more than 6 months. The com-
posite endpoint occurred in 6 (4.6%) patients: 2 deaths (both of cardiac
causes) and 4 myocardial infarctions. Three of them were under DAT, and the
3 others remained event free during 7, 240 and 270 days after clopidogrel
withdrawal. These findings suggest that DAT does not protect against death or
myocardial infarction. The rebound phenomenon after clopidogrel withdrawal
isn’t patent in our population.
Conclusion: In the Tunisian context, DAT observance is poor after
NSTE-ACS. Death and non fatal myocardial infarction don’t seem to be
reduced by DAT and the rebound phenomenon after clopidogrel with-
drawal isn’t patent. This may be in part attributed to the small sample of
population and the predominantly low risk (as assessed by TIMI risk
score), but larger studies are needed to strengthen the evidence for DAT
after NSTE-ACS.
